Another trial is evaluating amivantamab and capmatinib combination therapy in NSCLC patients with MET exon 14 skipping mutation and MET amplification (METalmark, NCT05488314) (www.clinicaltrial.gov, accessed on 14 May 2023). Here, MET is linked to non-small cell lung carcinoma.